Center for Scientific Review; Notice of Closed Meetings, 43858-43859 [2024-10987]
Download as PDF
<![CDATA[
43858
Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Notices
(e.g., growth promotion, feed efficiency),
and effects on the animal microbiome.
We specifically asked for feedback on
how we could modernize or improve
PPM 1240.3605, what challenges were
presented by this PPM, and what
additional types of claims or ingredients
CVM should consider during its review
of the policy. Many stakeholders
requested that we update our PPM to
provide for a larger set of ingredients
that can be safely used in animal food
to be treated other than as drugs and to
encourage innovation that supports
human and animal health, promotes
sustainable animal production, and
provides benefits to the environment.
After a thorough review of PPM
1240.3605, and careful consideration of
stakeholder feedback, FDA has
determined that PPM 1240.3605 no
longer reflects Agency current thinking
and is therefore withdrawing the PPM.
FDA encourages firms developing
animal food, nutritional ingredients, or
non-nutritive ingredients with intended
uses that could make them a drug,
including substances that are for use in
animal food and are intended to affect
the structure or any function of the
animal’s body, to contact the Agency
early in the product development
process. To contact FDA’s Center for
Veterinary Medicine about an animal
food substance intended to have the
effects described above, please email
animalfood-premarket@fda.hhs.gov.
FDA intends to issue guidance to
clarify our current thinking on the
regulation of certain substances that are
for use in animal food and are intended
to affect the structure or any function of
an animal’s body.
Dated: May 14, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
19:14 May 17, 2024
Jkt 262001
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–23–004
Human Islet Research Network—Consortium
on Modeling Autoimmune Diabetes (UG3/
UH3).
Date: June 26, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Tori Stone, Ph.D.,
Scientific Review Officer, National Institutes
of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD
20892, (301) 827–0994, tori.stone@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10992 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
[FR Doc. 2024–10936 Filed 5–17–24; 8:45 am]
VerDate Sep<11>2014
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of K99/R00 Applications.
Date: June 24–25, 2024.
Time: 10:00 a.m. to 6:00 p.m.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Tracy Koretsky, Ph.D.,
Scientific Review Officer, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, MSC
6200, Room 3AN12F, Bethesda, Maryland
20892, 301–594–2886, tracy.koretsky@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10988 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Promotion in Communities Study
Section.
Date: June 10–11, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave. NW, Washington, DC 20037 (In-Person
Meeting).
Contact Person: Helena Eryam Dagadu,
MPH, Ph.D., Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3137,
Bethesda, MD 20892, (301) 435–1266,
dagaduhe@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Community Influences on Health Behavior
Study Section.
Date: June 11–12, 2024.
E:\FR\FM\20MYN1.SGM
20MYN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Notices
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia E Ortenberg, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
Bethesda, MD 20892, 301–827–7189,
femiaee@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Neuronal Communications
Study Section.
Date: June 13–14, 2024.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852 (InPerson Meeting).
Contact Person: Prithi Rajan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 435–1042, prithi.rajan@nih.gov.
Name of Committee: Biology of
Development and Aging Integrated Review
Group; Drug Discovery and Molecular
Pharmacology C Study Section.
Date: June 13–14, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jeffrey Smiley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6194,
MSC 7804, Bethesda, MD 20892, (301) 272–
4596, smileyja@csr.nih.gov.
Name of Committee: Infectious Diseases
and Immunology B Integrated Review Group;
Hypersensitivity, Autoimmune, and Immunemediated Diseases Study Section.
Date: June 13–14, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Xinrui Li, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 594–2084,
xinrui.li@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Topics: Noninvasive Neuromodulation and
Neuroimaging Technologies.
Date: June 13–14, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (In-Person and Virtual
Meeting).
Contact Person: Pablo M. Blazquez Gamez,
Ph.D., Scientific Review Officer, Center for
VerDate Sep<11>2014
19:14 May 17, 2024
Jkt 262001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 435–1042,
pablo.blazquezgamez@nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Biobehavioral Regulation, Learning
and Ethology Study Section.
Date: June 13–14, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Louise Hargrave,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3170,
Bethesda, MD 20892, (301) 443–7193,
hargravesl@mail.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Cellular Immunotherapy of Cancer
Study Section.
Date: June 13–14, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shahana Majid, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 867–5309, shahana.majid@
nih.gov.
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
Cellular and Molecular Immunology—A
Study Section.
Date: June 13–14, 2024.
Time: 9:30 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Velasco Cimica, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–1760,
velasco.cimica@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–NS–
22–070—HEAL Initiative: Development and
Validation of Non-Rodent Mammalian
Models of Pain.
Date: June 13, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Kielczewski,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 435–1042, jennifer.kielczewski@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
43859
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10987 Filed 5–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: T Cell Receptor Fusion
Proteins for the Treatment of Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to INTcRON LLC
(‘‘INTcRON’’) located in Memphis,
Tennessee.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before June 4, 2024 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240) 276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 62/369,883 filed
August 2, 2016, entitled ‘‘Anti-KRAS
G12D T Cell Receptors’’ [HHS Reference
No. E–175–2016–0–US–01];
2. PCT Patent Application No. PCT/
US2017/044615 filed July 31, 2017,
entitled ‘‘Anti-KRAS G12D T Cell
Receptors’’ [HHS Reference No. E–175–
2016–0–PCT–02];
3. Australian Patent No. 2017306038
issued October 5, 2023, entitled ‘‘AntiKRAS G12D T Cell Receptors’’ [HHS
Reference No. E–175–2016–0–AU–03];
4. Canadian Patent Application No.
3,032,870 effective filing date of July 31,
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 89, Number 98 (Monday, May 20, 2024)]
[Notices]
[Pages 43858-43859]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10987]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Health Promotion in Communities Study
Section.
Date: June 10-11, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Ave. NW, Washington, DC
20037 (In-Person Meeting).
Contact Person: Helena Eryam Dagadu, MPH, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, (301)
435-1266, [email protected].
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Community Influences on Health Behavior
Study Section.
Date: June 11-12, 2024.
[[Page 43859]]
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elia E Ortenberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108, Bethesda, MD 20892, 301-
827-7189, [email protected].
Name of Committee: Molecular, Cellular and Developmental
Neuroscience Integrated Review Group; Neuronal Communications Study
Section.
Date: June 13-14, 2024.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852 (In-Person Meeting).
Contact Person: Prithi Rajan, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 435-1042,
[email protected].
Name of Committee: Biology of Development and Aging Integrated
Review Group; Drug Discovery and Molecular Pharmacology C Study
Section.
Date: June 13-14, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jeffrey Smiley, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD
20892, (301) 272-4596, [email protected].
Name of Committee: Infectious Diseases and Immunology B
Integrated Review Group; Hypersensitivity, Autoimmune, and Immune-
mediated Diseases Study Section.
Date: June 13-14, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Xinrui Li, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 594-2084,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Special Topics: Noninvasive Neuromodulation and Neuroimaging
Technologies.
Date: June 13-14, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (In-Person and Virtual Meeting).
Contact Person: Pablo M. Blazquez Gamez, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-1042,
[email protected].
Name of Committee: Biobehavioral and Behavioral Processes
Integrated Review Group; Biobehavioral Regulation, Learning and
Ethology Study Section.
Date: June 13-14, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Louise Hargrave, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institute of Health,
6701 Rockledge Drive, Room 3170, Bethesda, MD 20892, (301) 443-7193,
[email protected].
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Cellular Immunotherapy of Cancer Study Section.
Date: June 13-14, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shahana Majid, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 867-5309,
[email protected].
Name of Committee: Infectious Diseases and Immunology A
Integrated Review Group; Cellular and Molecular Immunology--A Study
Section.
Date: June 13-14, 2024.
Time: 9:30 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Velasco Cimica, Ph.D., Scientific Review
Officer, Center for Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301-594-1760, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA-NS-22-070--HEAL Initiative: Development and Validation of
Non-Rodent Mammalian Models of Pain.
Date: June 13, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Kielczewski, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-1042,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: May 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-10987 Filed 5-17-24; 8:45 am]
BILLING CODE 4140-01-P
